Study design
This randomized, open-label, multiple-dose, three-treatment,
three-period, six-sequence crossover study was conducted at Clinical
Trials Center of Seoul National University Hospital (Seoul, Republic of
Korea). Eligible subjects were randomly assigned to one of six treatment
sequence groups (Figure 1). Subjects received either evogliptin 5 mg
once daily for 7 days (EVO), pioglitazone 30 mg once daily for 7 days
(PIO), or coadministration of evogliptin 5 mg and pioglitazone 30 mg
once daily for 7 days (EVO+PIO) according to the assigned sequence and
period. Each treatment period was separated by 7 days of washout period.
Study drugs were administered with 150 mL of water under fasted state.